Your browser is no longer supported. Please, upgrade your browser.
Settings
MRTX Mirati Therapeutics, Inc. daily Stock Chart
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.69 Insider Own0.20% Shs Outstand40.27M Perf Week3.27%
Market Cap4.36B Forward P/E- EPS next Y-5.98 Insider Trans-91.36% Shs Float38.90M Perf Month3.29%
Income-169.20M PEG- EPS next Q-1.45 Inst Own- Short Float13.75% Perf Quarter26.57%
Sales6.30M P/S691.81 EPS this Y-14.40% Inst Trans-0.82% Short Ratio7.73 Perf Half Y14.46%
Book/sh11.08 P/B9.77 EPS next Y-12.20% ROA-44.80% Target Price114.54 Perf Year166.91%
Cash/sh11.28 P/C9.60 EPS next 5Y- ROE-48.60% 52W Range34.39 - 111.99 Perf YTD155.14%
Dividend- P/FCF- EPS past 5Y7.80% ROI- 52W High-4.75% Beta2.12
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low210.19% ATR4.98
Employees63 Current Ratio13.10 Sales Q/Q- Oper. Margin- RSI (14)62.56 Volatility4.66% 5.15%
OptionableYes Debt/Eq0.00 EPS Q/Q-62.80% Profit Margin- Rel Volume0.35 Prev Close108.23
ShortableYes LT Debt/Eq0.00 EarningsNov 05 Payout- Avg Volume691.74K Price106.68
Recom1.90 SMA207.45% SMA5018.52% SMA20024.81% Volume171,103 Change-1.44%
Sep-24-19Upgrade Guggenheim Neutral → Buy $116
Sep-09-19Upgrade Jefferies Hold → Buy $89 → $105
Aug-02-19Downgrade JP Morgan Neutral → Underweight $85
Jul-18-19Initiated Deutsche Bank Hold $86
Jun-19-19Downgrade B. Riley FBR Buy → Neutral $60 → $92
Jun-07-19Downgrade Guggenheim Buy → Neutral
Jun-05-19Reiterated H.C. Wainwright Buy $84 → $117
Jun-04-19Upgrade Citigroup Neutral → Buy $76 → $132
Apr-17-19Initiated JP Morgan Neutral $72
Mar-25-19Initiated Credit Suisse Outperform $85
Mar-04-19Downgrade Citigroup Buy → Neutral $64 → $77
Feb-15-19Initiated Piper Jaffray Overweight $85
Dec-03-18Initiated B. Riley FBR Buy $60
Oct-29-18Upgrade Guggenheim Neutral → Buy
Jul-09-18Reiterated Oppenheimer Outperform $35 → $62
Mar-12-18Initiated Barclays Overweight $44
Jan-09-18Reiterated H.C. Wainwright Buy $17 → $21
Nov-14-17Upgrade Leerink Partners Mkt Perform → Outperform
Oct-12-17Resumed H.C. Wainwright Buy $20
Sep-19-17Initiated Oppenheimer Outperform $18
Dec-04-19 08:35PM  Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Nov-09-19 06:15PM  Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting PR Newswire
Nov-04-19 06:55PM  Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM  Mirati Therapeutics Reports Third Quarter 2019 Financial Results PR Newswire
Nov-03-19 07:10AM  The Mirati Therapeutics (NASDAQ:MRTX) Share Price Gained 1921% And Shareholders Are Jubilant Simply Wall St.
Oct-29-19 07:32AM  The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga +16.73%
Oct-28-19 04:15PM  Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics PR Newswire
04:15PM  Mirati drug shrinks tumors in some cancer patients in early-stage trial Reuters
Oct-25-19 11:05AM  Mirati Therapeutics, Inc. (MRTX): Are Hedge Funds Right About This Stock? Insider Monkey +6.10%
Oct-23-19 04:45PM  Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting PR Newswire
Oct-17-19 09:00AM  Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics PR Newswire +8.35%
Oct-16-19 04:22PM  Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts Benzinga
Oct-07-19 06:00AM  After 500% Surge, Miratis Day of Reckoning Is Approaching Bloomberg
Oct-01-19 09:09AM  Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock? Zacks -8.87%
Sep-28-19 08:34AM  Here's Why We're Not Too Worried About Mirati Therapeutics's (NASDAQ:MRTX) Cash Burn Situation Simply Wall St.
Sep-09-19 10:10AM  Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group Zacks -5.24%
Sep-05-19 09:16PM  4 Biotech Stocks With Big Catalysts in September Motley Fool
Sep-04-19 09:15AM  Amgens White Whale Cancer Data May Send Shares to Record High Bloomberg
Aug-23-19 10:15PM  Mirati Therapeutics Inc (MRTX) President & CEO Charles M Baum Sold $4.5 million of Shares GuruFocus.com
09:38AM  A Look At The Intrinsic Value Of Mirati Therapeutics, Inc. (NASDAQ:MRTX) Simply Wall St.
Aug-15-19 04:30PM  Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources PR Newswire
Aug-05-19 04:15PM  Mirati Therapeutics Reports Second Quarter 2019 Financial Results PR Newswire
Jul-18-19 07:35AM  Is Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay Fair? Simply Wall St.
Jul-10-19 05:53PM  Mirati Inks Deal with Novartis to Evaluate Tumor Candidate Zacks
04:41PM  How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug Investor's Business Daily
07:17AM  The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV Benzinga
Jul-09-19 04:30PM  Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155 PR Newswire
Jul-02-19 07:29AM  The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug Benzinga
Jul-01-19 04:30PM  Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors PR Newswire
Jun-30-19 08:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-27-19 04:05PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jun-25-19 08:30AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jun-24-19 04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
09:43AM  Read This Before You Buy Any New Cancer Drug Stocks Motley Fool
Jun-18-19 07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-14-19 08:41AM  Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options Zacks
Jun-13-19 11:51AM  3 Under-the-Radar Stocks Trading at All-Time Highs Investopedia
Jun-12-19 10:03AM  Mirati Therapeutics, Inc. (NASDAQ:MRTX): Financial Strength Analysis Simply Wall St.
Jun-10-19 10:26AM  Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Jun-06-19 03:12PM  Mirati Therapeutics Could Soar Even Higher TheStreet.com
Jun-05-19 07:30AM  The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache Benzinga
Jun-04-19 03:18PM  The 10 Best Stocks for 2019 So Far InvestorPlace +9.90%
12:37PM  Amgens Good News on Lung Cancer Boosted Mirati Therapeutics. Heres What Wall Street Is Saying. Barrons.com
10:53AM  How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's? Benzinga
10:19AM  Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity Zacks
09:21AM  3 Cancer Stocks Given a Lift by Amgen Motley Fool
Jun-03-19 02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks +31.58%
12:47PM  Amgen Stock Jumps on Promising Cancer Drug Trial Results Barrons.com
12:18PM  Here's Why Mirati Therapeutics Is Jumping Today Motley Fool
May-31-19 01:04PM  What to watch at the world's largest cancer conference CNBC Videos
May-30-19 04:30PM  Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference PR Newswire
May-16-19 04:14PM  Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting Investor's Business Daily +11.13%
02:47PM  Here's Why Mirati Therapeutics Is Surging Today Motley Fool
10:47AM  What's Triggering The Rise In Mirati Shares? Benzinga
May-14-19 08:42AM  Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock Zacks
May-07-19 07:10AM  What You Must Know About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Beta Value Simply Wall St.
Apr-29-19 05:10PM  Mirati: 1Q Earnings Snapshot Associated Press
04:05PM  Mirati Therapeutics Reports First Quarter 2019 Financial Results PR Newswire
02:52PM  Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. (MRTX) ? Insider Monkey
Apr-01-19 04:30PM  Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference PR Newswire
Mar-26-19 12:21PM  The Mirati Therapeutics (NASDAQ:MRTX) Share Price Has Gained 287%, So Why Not Pay It Some Attention? Simply Wall St.
Mar-05-19 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
Feb-28-19 04:15PM  Mirati Therapeutics Reports Fourth Quarter Financial Results PR Newswire -5.02%
Feb-25-19 08:10AM  Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-19-19 04:15PM  Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors PR Newswire
Feb-07-19 04:30PM  Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day PR Newswire
Feb-04-19 05:01PM  Here's Why Mirati Therapeutics Jumped 55.8% in January Motley Fool
Jan-31-19 07:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics ACCESSWIRE
Jan-30-19 11:41AM  How Many Insiders Sold Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares? Simply Wall St. +5.31%
Jan-23-19 07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
Jan-22-19 04:01PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jan-17-19 08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga
Jan-16-19 08:45PM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
04:01PM  Mirati Therapeutics Announces Proposed Public Offering Of Common Stock PR Newswire
Jan-15-19 04:21PM  Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor PR Newswire
07:55AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics ACCESSWIRE
Jan-10-19 06:00AM  Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause ACCESSWIRE +13.27%
Jan-09-19 08:39AM  Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4% Zacks +5.46%
Jan-07-19 08:30AM  Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®) PR Newswire +7.31%
Jan-02-19 04:30PM  Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference PR Newswire +5.26%
Dec-20-18 04:42PM  Mirati Therapeutics Added To NASDAQ Biotechnology Index PR Newswire
Dec-12-18 03:27AM  Hedge Funds Are Buying Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Dec-10-18 04:15PM  Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors PR Newswire
Dec-04-18 07:20AM  Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar Discovering Underlying Factors of Influence GlobeNewswire
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
Nov-29-18 05:20PM  Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849 PR Newswire -5.56%
Nov-20-18 04:30PM  Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-09-18 08:35AM  Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting PR Newswire -5.65%
08:30AM  Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting PR Newswire
Nov-08-18 04:32PM  Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors PR Newswire
Nov-07-18 09:00AM  Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference PR Newswire +6.95%
Nov-06-18 06:52PM  Mirati: 3Q Earnings Snapshot Associated Press
04:15PM  Mirati Therapeutics Reports Third Quarter Financial Results PR Newswire
Nov-05-18 04:15PM  Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting PR Newswire
Oct-30-18 09:00AM  Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer PR Newswire +6.11%
Oct-25-18 08:50AM  Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.50%
Oct-22-18 04:49PM  Mirati Shares Fall After Cancer Trial Progress Report TheStreet.com -15.00%
04:45PM  Biotech Dives After Lung Cancer Regimen With Bristol Disappoints Investor's Business Daily
04:26PM  These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests Investor's Business Daily
11:51AM  Why Mirati Therapeutics Inc. Is Plunging Today Motley Fool
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a Clinical Collaboration Agreement with Novartis International AG. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARTER BRUCE L ADirectorNov 20Option Exercise6.783,00020,3403,000Nov 22 04:46 PM
CARTER BRUCE L ADirectorNov 20Sale94.743,000284,2200Nov 22 04:46 PM
GREY MICHAEL GDirectorNov 12Option Exercise16.843,50058,9405,298Nov 14 06:30 PM
GREY MICHAEL GDirectorNov 12Sale102.443,042311,6222,256Nov 14 06:30 PM
BAUM CHARLES MPresident & CEOAug 22Option Exercise8.6752,368454,290117,851Aug 23 06:07 PM
BAUM CHARLES MPresident & CEOAug 22Sale86.2251,8104,467,31266,041Aug 23 06:07 PM
CARTER BRUCE L ADirectorAug 21Option Exercise6.783,00020,3403,000Aug 23 06:01 PM
CARTER BRUCE L ADirectorAug 21Sale89.243,000267,7200Aug 23 06:01 PM
GREY MICHAEL GDirectorAug 12Option Exercise16.843,50058,9404,840Aug 14 07:30 PM
GREY MICHAEL GDirectorAug 12Sale92.273,042280,6971,798Aug 14 07:30 PM
Avoro Capital Advisors LLC10% OwnerJul 23Sale101.8862,5006,367,5003,800,000Jul 25 04:33 PM
Boxer Capital, LLC10% OwnerJul 17Sale98.30725,00871,268,328990,560Jul 19 09:39 PM
CARTER BRUCE L ADirectorMay 22Option Exercise6.783,00020,3403,000May 24 05:00 PM
CARTER BRUCE L ADirectorMay 22Sale75.203,000225,5970May 24 05:00 PM
Donadio Jamie ASr. VP, CFOMay 16Option Exercise5.507,50041,2507,721May 20 07:00 PM
Donadio Jamie ASr. VP, CFOMay 16Sale75.007,500562,500221May 20 07:00 PM
GREY MICHAEL GDirectorMay 13Option Exercise16.847,100119,5647,100May 15 07:00 PM
GREY MICHAEL GDirectorMay 13Sale65.305,760376,1381,340May 15 07:00 PM
venBio Select Advisor LLC10% OwnerMar 20Sale72.8023,7811,731,2573,862,500Mar 20 04:05 PM
venBio Select Advisor LLC10% OwnerMar 19Sale73.43100,0007,343,0003,886,281Mar 20 04:05 PM
venBio Select Advisor LLC10% OwnerMar 18Sale76.55125,0009,568,7503,986,281Mar 20 04:05 PM
Braslyn Ltd.10% OwnerMar 01Option Exercise0.00275,0042753,135,970Mar 05 09:30 PM
Boxer Capital, LLC10% OwnerMar 01Option Exercise0.00425,0064251,715,566Mar 05 09:30 PM
Boxer Capital, LLC10% OwnerMar 01Sale69.00425,00029,325,0001,290,560Mar 05 09:30 PM
Braslyn Ltd.10% OwnerMar 01Sale69.00275,00018,975,0002,860,966Mar 05 09:30 PM
BAUM CHARLES MPresident & CEOFeb 25Option Exercise8.5051,810440,385117,851Feb 27 07:00 PM
BAUM CHARLES MPresident & CEOFeb 25Sale75.6751,8103,920,67266,041Feb 27 07:00 PM
BAUM CHARLES MPresident & CEOFeb 21Option Exercise21.583,62378,17366,041Feb 25 08:04 PM
CARTER BRUCE L ADirectorFeb 20Option Exercise6.783,00020,3403,000Feb 22 07:00 PM
venBio Select Advisor LLC10% OwnerFeb 20Sale73.00686,82050,137,8604,111,281Feb 21 04:10 PM
CARTER BRUCE L ADirectorFeb 20Sale73.643,000220,9210Feb 22 07:00 PM
Donadio Jamie ASr. VP, CFOFeb 15Option Exercise5.407,50040,5007,721Feb 19 07:00 PM
Donadio Jamie ASr. VP, CFOFeb 15Sale75.007,500562,502221Feb 19 07:00 PM
LEMASTERS CHRISTOPHER C.EVP, Chief Business OfficerFeb 14Option Exercise6.4560,000387,00060,000Feb 19 07:00 PM
LEMASTERS CHRISTOPHER C.EVP, Chief Business OfficerFeb 14Sale71.7760,0004,306,4550Feb 19 07:00 PM
Johnson Craig ADirectorJan 29Option Exercise8.6517,000147,03017,000Jan 31 07:00 PM
Johnson Craig ADirectorJan 29Sale61.4617,0001,044,7730Jan 31 07:00 PM
CHEN ISANEVP, Chief Medical OfficerJan 23Option Exercise22.4787019,54735,836Jan 25 07:00 PM
Boxer Capital, LLC10% OwnerJan 17Buy62.00150,0009,300,0001,715,560Jan 22 05:34 PM
Reisman Neil10% OwnerJan 11Option Exercise12.8925,972334,68739,103Jan 15 09:15 PM
Boxer Capital, LLC10% OwnerJan 09Option Exercise0.00150,0031501,565,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 09Sale51.55150,0007,732,1001,415,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 08Option Exercise0.00550,0125501,565,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 08Sale52.10550,00028,657,0721,015,560Jan 09 09:31 PM
Davis Aaron I.DirectorJan 08Sale52.8010,000528,00037,052Jan 09 09:31 PM
Davis Aaron I.DirectorJan 07Sale46.4040,0001,855,80347,052Jan 09 09:31 PM
Christensen JamieEVP, Chief Scientific OfficerDec 26Option Exercise17.415,16989,9928,789Dec 28 07:00 PM